CRISPR Therapeutics AG (CRSP)

Comment l'entreprise gagne de l'argent

CRISPR Therapeutics earns most of its money not from selling a product itself, but from its share of Casgevy's profits and losses under a 60/40 arrangement with Vertex, which manufactures, markets and books the product's own commercial revenue. The company also collects upfront and milestone payments from research collaborations. Its own pipeline programmes are pre-revenue and consume cash through clinical trials, so overall revenue is small, uneven, and depends on Vertex's commercial execution rather than on sales the company controls directly.

Principaux risques

• Early-stage gene editing technology and clinical trial risk — The company states that CRISPR/Cas9 gene editing is a relatively new technology with a limited history of clinical trials, making it hard to predict how long or how much it will cost to develop new product candidates, or whether past trial results will be repeated in future studies.
• Regulatory caution toward gene therapy — The company states that regulators including the FDA and EMA have shown caution toward gene therapy, and that ethical and legal concerns could lead to additional restrictions on developing or commercializing its product candidates.
• Dependence on Vertex for Casgevy — Vertex leads global development, manufacturing and commercialization of Casgevy and books its revenue directly, sharing program costs and profits 60/40 with CRISPR Therapeutics, which does not control the pace or quality of the product's commercial rollout.
• Intellectual property uncertainty — The company states it faces uncertainty over intellectual property protection for its gene editing technology, including third-party patent rights relevant to CRISPR/Cas9 that have been the subject of ongoing interference proceedings.

The company does not report a numeric customer split, but structurally almost all near-term revenue depends on a single partner, Vertex, which leads Casgevy's global development, manufacturing and commercialization.